JP2020505465A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505465A5
JP2020505465A5 JP2019560493A JP2019560493A JP2020505465A5 JP 2020505465 A5 JP2020505465 A5 JP 2020505465A5 JP 2019560493 A JP2019560493 A JP 2019560493A JP 2019560493 A JP2019560493 A JP 2019560493A JP 2020505465 A5 JP2020505465 A5 JP 2020505465A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019560493A
Other languages
English (en)
Japanese (ja)
Other versions
JP7140403B2 (ja
JP2020505465A (ja
Filing date
Publication date
Priority claimed from GBGB1701194.1A external-priority patent/GB201701194D0/en
Application filed filed Critical
Publication of JP2020505465A publication Critical patent/JP2020505465A/ja
Publication of JP2020505465A5 publication Critical patent/JP2020505465A5/ja
Application granted granted Critical
Publication of JP7140403B2 publication Critical patent/JP7140403B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019560493A 2017-01-24 2018-01-24 Lightに結合する抗原結合分子 Active JP7140403B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1701194.1 2017-01-24
GBGB1701194.1A GB201701194D0 (en) 2017-01-24 2017-01-24 Antigen binding molecules that bind light
PCT/GB2018/050203 WO2018138496A1 (en) 2017-01-24 2018-01-24 Antigen binding molecules that bind light

Publications (3)

Publication Number Publication Date
JP2020505465A JP2020505465A (ja) 2020-02-20
JP2020505465A5 true JP2020505465A5 (https=) 2021-03-11
JP7140403B2 JP7140403B2 (ja) 2022-09-21

Family

ID=58463068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019560493A Active JP7140403B2 (ja) 2017-01-24 2018-01-24 Lightに結合する抗原結合分子

Country Status (7)

Country Link
US (2) US11827673B2 (https=)
EP (1) EP3574014A1 (https=)
JP (1) JP7140403B2 (https=)
KR (1) KR20190110578A (https=)
CN (1) CN110461875B (https=)
GB (2) GB201701194D0 (https=)
WO (1) WO2018138496A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114516913B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测试剂盒
CN116355860A (zh) * 2021-12-28 2023-06-30 四川远大蜀阳药业有限责任公司 分泌抗h因子抗体的杂交瘤细胞株、抗h因子抗体及其应用
WO2025195445A1 (zh) * 2024-03-21 2025-09-25 北京三诺佳邑生物技术有限责任公司 特异性结合light和tslp的多特异性抗体以及组合物及其应用
KR20250151071A (ko) 2024-04-13 2025-10-21 백수경 이동식 방제 박스
WO2026050470A1 (en) * 2024-08-28 2026-03-05 Earendil Labs Inc. A bispecific antibody and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3734795A (en) 1971-04-23 1973-05-22 Lindsay Wire Weaving Co Patch and seam for plastic belts
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
WO1998047343A2 (en) 1997-04-04 1998-10-29 Biosite Diagnostics, Inc. Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages
US6140467A (en) 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DE60143231D1 (de) 2000-04-12 2010-11-18 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden Proteins von Herpes Simplex und Methoden zu dessen Verwendungen
EP1336619A3 (en) 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
EP1499353A4 (en) * 2002-04-15 2006-04-05 Human Genome Sciences Inc SPECIFIC TO TL5 BINDING ANTIBODIES
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
SI2292663T1 (sl) * 2006-08-28 2014-02-28 Kyowa Hakko Kirin Co., Ltd Antagonistična humana monoklonska protitelesa, specifična za humani LIGHT
US8440185B2 (en) 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー/エス 安定なIgG4抗体
US20090136427A1 (en) 2007-09-18 2009-05-28 La Jolla Institute For Allergy And Immunology LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment
WO2010051502A2 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
EP4527855A3 (en) 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
WO2013148350A2 (en) * 2012-03-26 2013-10-03 Sanofi Anti-light antibody therapy for inflammatory bowel disease
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP3041831B1 (en) 2013-09-06 2019-10-23 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease
EA201690746A1 (ru) 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
EP3094651B1 (en) 2014-01-14 2020-03-11 Kymab Limited Anti-light antibodies
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
WO2016127059A2 (en) 2015-02-05 2016-08-11 La Jolla Institute For Allergy And Immunology Light inhibitors for scleroderma and skin fibrotic disease treatment
EP3730188B1 (en) 2015-08-21 2024-07-31 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
US11312781B2 (en) * 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT

Similar Documents

Publication Publication Date Title
JP2020505465A5 (https=)
CN109195993B (zh) 串联fab免疫球蛋白及其用途
TWI687440B (zh) St2l拮抗劑及使用方法
JP2020513791A5 (https=)
AU2015322141B2 (en) High affinity and aggregatively stable antibodies on the basis of variable domains Vl and a derivative VHH
JP2014534218A5 (https=)
JP2012501670A5 (https=)
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
HRP20191219T1 (hr) Molekule protutijela koje imaju specifičnost za ljudski ox40
JP2012524071A5 (https=)
HRP20170041T1 (hr) Anti-c5a vezujuće grupe s visokom blokirajućom aktivnošću
JP2010526028A5 (https=)
JP2014500009A5 (https=)
CA2896548A1 (en) Multivalent binding protein compositions
JP2014509510A5 (https=)
CN114144431B (zh) 人源化抗TNFα抗体及其用途
JP2025500971A5 (https=)
JP2012531922A5 (ja) Toll様受容体2へのヒト化抗体またはその抗原結合部位
JP2014519334A5 (https=)
JP2011527899A5 (https=)
JP2016520595A5 (https=)
JP2015537190A5 (https=)
JP2024532495A (ja) 抗ヒトtslpモノクローナル抗体及びその使用
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
RU2019126888A (ru) Антитело к человеческому аннексину а1